BioNxt Solutions寻求在欧亚和欧洲市场针对高MS区域进行口服薄膜处理的独家许可。 BioNxt Solutions seeks exclusive licensing for its oral thin film treatment in Eurasian and European markets, targeting high-MS regions.

经欧亚专利组织授予专利后,BioNxt Solutions Inc. 签署了一份不具约束力的意向书,在一个或多个欧亚专利组织成员国探索对其子语言克拉迪宾口服薄膜的专有许可. BioNxt Solutions Inc. has signed a non-binding letter of intent to explore exclusive licensing for its sublingual cladribine oral thin film in one or more Eurasian Patent Organization member states, following patent grants in both the Eurasian region and Europe. 2025年11月生效的EAPO专利涵盖人口超过2亿的8个国家,2043年到期。 The EAPO patent, effective November 2025, covers eight countries with over 200 million people and expires in 2043. EPO于2026年3月11日授予相关专利,到2043年可能覆盖多达39个欧洲国家。 The EPO granted a related patent on March 11, 2026, potentially covering up to 39 European countries through 2043. 60天谈判期间的重点是潜在的交易,涉及预付付款、特许使用费以及监管、制造和商业化努力方面的合作。 The 60-day negotiation period focuses on a potential deal involving upfront payments, royalties, and collaboration on regulatory, manufacturing, and commercialization efforts. 该公司将目标对准神经和自动免疫条件(如多发性硬化症)比率很高的市场,影响到全球约290万人。 The company is targeting markets with high rates of neurological and autoimmune conditions like Multiple Sclerosis, affecting about 2.9 million people globally.